COMBINATION OF BECLOMETHASONE AND FORMOTEROL VIA NEXTHALER: SATISFACTION, EFFECTS ON ADHERENCE, ASTHMA CONTROL AND QUALITY OF LIFE

Abstract

This was a 6-month prospective, multicenter, open-label, observational study in 661 patients with asthma not well controlled by low-dose ICS according to the physician’s clinical assessment, which has received regular treatment with extrafine BDP/F NEXThaler. Feeling of Satisfaction with the Inhaler, treatment adherence, asthma control, lung function and QoL were recorded at baseline, 3 and 6 months after treatment with extra-fine BDP/F. The percentage of patients at least “fairly” satisfied with NEXThaler usability was 96.3 %. Approximately 67 % of the patients reported “high adherence” after 3 months of study treatment, and 70 % of them reported “high adherence” after 6 months of study treatment. The percentage of patients with ACQ-6-uncontrolled asthma decreased from 79.1 % to 22.3 % after 3 months of study treatment and further decreased to 6.7 % after 6 months of study treatment. Significant improvements were also observed in the total score of quality of life, lung function and reduction in rescue medication use.